Page last updated: 2024-09-05

erlotinib hydrochloride and epirubicin

erlotinib hydrochloride has been researched along with epirubicin in 2 studies

Compound Research Comparison

Studies (erlotinib hydrochloride)	Trials (erlotinib hydrochloride)	Recent Studies (post-2010) (erlotinib hydrochloride)	Studies (epirubicin)	Trials (epirubicin)	Recent Studies (post-2010) (epirubicin)
4,353	786	3,033	5,453	1,838	1,570

Protein Interaction Comparison

Protein	Taxonomy	erlotinib hydrochloride (IC50)	epirubicin (IC50)
Genome polyprotein			0.75
Tyrosine-protein kinase Fyn	Homo sapiens (human)		5.181

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Collignon, J; Delvenne, P; Donneau, AF; Feyereisen, E; Foidart, P; Gofflot, S; Jerusalem, G; Lienard, M; Noël, A; Schroeder, H; Somja, J; Sounni, NE; Truong, A; Yip, C	1
Hou, E; Lai, L; Lu, Y; Meng, W; Tan, Z; Wei, J; Zhang, X	1

Other Studies

2 other study(ies) available for erlotinib hydrochloride and epirubicin

Article	Year
MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib. British journal of cancer, 2017, Mar-14, Volume: 116, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Epirubicin; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Matrix Metalloproteinases, Membrane-Associated; Mice; Mice, Nude; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays	2017
Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports. Medicine, 2021, Mar-12, Volume: 100, Issue:10 Topics: Acrylamides; Adult; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; Epirubicin; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Pneumonectomy; Protein Kinase Inhibitors; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Treatment Outcome	2021

Article

Year

MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.

British journal of cancer, 2017, Mar-14, Volume: 116, Issue:6

Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Epirubicin; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Matrix Metalloproteinases, Membrane-Associated; Mice; Mice, Nude; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2017

Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports.

Medicine, 2021, Mar-12, Volume: 100, Issue:10

Topics: Acrylamides; Adult; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; Epirubicin; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Pneumonectomy; Protein Kinase Inhibitors; Small Cell Lung Carcinoma; Tomography, X-Ray Computed; Treatment Outcome

2021